Stock Events

Applied Dna Sciences 

$0.44
57
+$0.02+5.21% Friday 19:59

统计数据

当日最高
0.45
当日最低
0.39
52周最高
37.2
52周最低
0.33
成交量
1,378,334
平均成交量
1,523,281
市值
3.97M
市盈率
0
股息收益率
-
股息
-

收益

10May已确认
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-4.5
-3
-1.51
-0.01
预期每股收益
-4.5
实际每股收益
-2.71

人们还关注

此列表基于关注APDN的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

分析师评级

1.5$平均价格目标
最高估值为 $1.5。
来自过去6个月内的 1 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%

关于

Information Technology Services
Pharmaceuticals: Major
Technology Services
Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Miscellaneous Commercial Services
Commercial Services
Manufacturing
Health Technology
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Show more...
首席执行官
James Hayward
员工
52
国家
US
ISIN
US03815U3005
WKN
000A2PUTA

上市公司